Revolution Medicines reveals zoldonrasib 82% response rate

• Revolution Medicines reported a treatment response rate of up to 82% for its zoldonrasib combinations.
• Following the presentation, shares of the company traded upward to reach $188.03.
• The company stated that these oncology data points support its upcoming Phase 3 trials.

Revolution Medicines (NASDAQ:RVMD) reported Phase 1/2 data showing up to an 82% response rate for zoldonrasib combinations.

The presentation at the ESMO GI 2026 Congress highlighted results for patients with RAS G12D metastatic pancreatic cancer.

Pretreated patients receiving zoldonrasib plus daraxonrasib achieved an objective response rate between 47% and 50% during the trial.

The evaluated treatments specifically block oncogenic variants to stop the growth of diverse tumor cells.

The company stated that these early findings will guide its broader regulatory and development pipelines.

The company stated that the findings support its pivotal Phase 3 RASolute 305 and RASolute 309 clinical trials.